Peptides DB
Research-centric peptide and protocol reference hub
Study 12 of 43Vasopressin literaturebiorxiv-preprint · Observational2026

The Aiko–Takeru (AT) Model: A Kidney-Level Flux–Balance Framework for Asymmetric PKD Progression

The Aiko–Takeru Model suggests that kidney-specific differences in drainage efficiency may influence the progression of polycystic kidney disease, rather than systemic vasopressin levels alone.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the vasopressin corpus
9
Preclinical
30
Observational · this one
1
Open-label
2
Randomised
1
Reviews

Summary and findings

This study investigates the physiological basis of asymmetric progression in polycystic kidney disease (PKD) using the Aiko–Takeru (AT) Model. Longitudinal data were collected over three years from a feline PKD subject receiving sustained subcutaneous fluid therapy. The study emphasizes kidney-specific dynamics rather than solely systemic vasopressin exposure.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.n=12026

Abstract

The authors’ words, as biorxiv-preprint supplied them

Abstract Asymmetric progression between kidneys has been observed in polycystic kidney disease (PKD), yet its physiological basis remains incompletely understood under models emphasizing systemic vasopressin exposure. The Aiko–Takeru (AT) Model presents a flux–balance framework in which cyst progression is governed by a flux–balance between vasopressindependent inflow and drainage-dependent clearance at the kidney level. Longitudinal multimodal data were collected over three years from a feline PKD subject receiving sustained subcutaneous fluid therapy, including MRI-based cyst volumetry, ultrasound measurements, plasma arginine vasopressin (AVP) concentrations, plasma osmolality, and renal biomarkers. A unilateral ureteral anastomosis created kidney-specific drainage asymmetry, enabling evaluation of kidney-specific dynamics. The AT Model provided a framework for interpreting two features of the dataset: (1) AVP fluctuations despite stable plasma osmolality, motivating exploration of influences beyond osmolality; and (2) asymmetric cyst volume progression between kidneys under systemic conditions. Within the model, divergence may be associated with kidney-specific differences in drainage efficiency rather than systemic vasopressin exposure alone. Derived from a single feline case, the framework is grounded in physiological principles and provides a structure for investigating kidney-specific progression mechanisms in PKD. The flux–balance formulation suggests that asymmetric PKD progression may involve kidney-specific differences in drainage efficiency beyond systemic hormonal exposure alone.

Background

This paper addresses the phenomenon of asymmetric progression in polycystic kidney disease (PKD), which has been noted but not fully understood in terms of its physiological mechanisms. Previous models have primarily focused on systemic vasopressin exposure, leaving gaps in understanding kidney-specific dynamics. The introduction of the Aiko–Takeru (AT) Model aims to provide a new framework for exploring these dynamics at the kidney level.

Methods

The study utilized a longitudinal design, collecting multimodal data from a single feline PKD subject over three years. The subject received sustained subcutaneous fluid therapy, and various measurements were taken, including MRI-based cyst volumetry and plasma arginine vasopressin concentrations. A unilateral ureteral anastomosis was performed to create kidney-specific drainage asymmetry.

Results

The study reported fluctuations in plasma arginine vasopressin (AVP) concentrations despite stable plasma osmolality. Asymmetric cyst volume progression was observed between the kidneys, suggesting that kidney-specific differences in drainage efficiency may play a role in PKD progression.

Interpretation

The findings suggest that kidney-specific dynamics may be more influential in PKD progression than previously thought, challenging the notion that systemic vasopressin exposure is the primary driver. However, the study's reliance on a single case limits the ability to draw broader conclusions. The effect sizes and clinical significance of the observed phenomena are not quantified, which further complicates the interpretation.

Key findings

  • Longitudinal multimodal data collected over three years.
  • Fluctuations in plasma arginine vasopressin (AVP) despite stable plasma osmolality.
  • Asymmetric cyst volume progression observed between kidneys.

Limitations

  • Findings derived from a single feline case.
  • No specific numeric outcomes or statistical analyses reported.
  • Limited generalizability to human PKD patients.

Elsewhere in the Vasopressin corpus

BAcute colonic pseudo-obstruction with transient failure of oral desmopressin in adipsic arginine vasopressin deficiency.JCEM case reports · 2023 · n=1 · Not reported in abstract.HumanAEffect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial.JAMA · 2026 · Mortality at 28 days was 31.8% in the lower-threshold group vs 33.0% in the higher-threshold group, P=0.62.HumanDVasopressin in Septic Shock-Is Early the Right Question?JAMA · 2026—DEffect of Vasopressin Initiation Threshold on Septic Shock Mortality: Research Summary.JAMA · 2026reviewAImpact of a Capillary Refill Time–Guided Personalised Hemodynamic Resuscitation Protocol in Septic Shock in Low- and Middle-Income Countries: A Post Hoc Analysis of the ANDROMEDA-SHOCK-2 Trialbiorxiv-preprint · 2023 · n=1467 · Win ratio of 1.16 (95% CI 1.14–1.18) in LMICs.HumanBA corticopapillary Gdf15 response links maladaptive collecting duct remodeling to polyuria during lithium exposurebiorxiv-preprint · 2026 · Not reported in abstract.Human